Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991)

Leukemia
M C PettiF Malagnino

Abstract

The 'gold standard' for the treatment of polycythemia vera (PV) is to date undefined. We performed a retrospective analysis to evaluate the outcome of a cohort of PV patients treated with pipobroman (PB) at a single institution during a period of 20 years (November 1971-October 1991). During this period, a total of 366 adult PV patients were diagnosed according to Polycythemia Vera Study Group (PVSG) criteria. Of these, only 199 (54%) were treated with PB: 92 were males and 107 females, median age was 63.0 years (range 25.2-87.3 years). Major clinical characteristics at onset were as follows: 34 (17%) patients had splenomegaly >3 cm below costal margin, 70 (35%) had platelets >600,000/mm3, 79 (40%) had white blood cells >12,000 mm3; 97 (49%) had hypertension, 83 (42%) had minor neurological symptoms (as vertigo, headache, paresthesias), 33 (17%) had pruritus and 27 (13%) had thrombotic features. All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females). Thereafter treatment was given according to toxicity and maintenance of response. All patients were phlebotomized before starting treatment (mean number of phlebotomies performed: three, range 2-4) and ...Continue Reading

Citations

May 5, 1999·Critical Reviews in Oncology/hematology·T Barbui, G Finazzi
Feb 14, 2002·British Journal of Haematology·Jerry L Spivak
Dec 1, 2009·Journal of Medical Case Reports·Ming-Shyan LinPao-Hsien Chu
Sep 13, 2000·Drugs & Aging·P J van Genderen, M M Troost
Oct 21, 2003·Leukemia & Lymphoma·Francesco Passamonti, Mario Lazzarino
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Feb 14, 2003·Mayo Clinic Proceedings·Ayalew Tefferi
Jan 23, 2015·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Mar 14, 2007·Hematological Oncology·Mary Frances McMullin
Jul 6, 2010·European Journal of Clinical Investigation·Kamal S SainiAyalew Tefferi
Apr 24, 2016·Annals of Hematology·Brianna E VaaAlexandra P Wolanskyj
Jul 13, 2016·Critical Reviews in Oncology/hematology·Aziz NazhaNaval Daver
Dec 20, 2016·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Oct 4, 2018·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Dec 1, 2007·The British Journal of Dermatology·J HafijiN P Burrows
Sep 26, 2020·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Expert Opinion on Emerging Drugs
Raoul Tibes, Ruben A Mesa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E BrusamolinoC Bernasconi
© 2022 Meta ULC. All rights reserved